KCT0008301
Recruiting
未知
Clinical Research of Anti-Tumor Activity and Safety of Autologous Vax-NK/HCC Consolidation Therapy Following First- line Chemoimmunotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Chonnam National University Hospital Hwasun Hospital0 sites12 target enrollmentTBD
ConditionsNeoplasms
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Chonnam National University Hospital Hwasun Hospital
- Enrollment
- 12
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients who are histologically or cytologically confirmed to have extensive stage small cell lung cancer.
- •2\) Patients with no tumor progression observed after 4 cycles of the first\-line chemoimmunotherapy (ACE regimen)
- •3\) an adult over the age of 19
- •4\) Patients with ECOG performance score below 2
- •5\) Patients who have signed and agreed to participate in this clinical study
- •6\) A patient who has obtained a consent form for donation to the Biobank of Chonnam National University Hwasun Hospital
- •7\) Patients who meet the following conditions in a blood test.
- •\- Absolute neutrophil count (ANC) \= 1\.0 x 10^9/L
- •\- White blood cells count (WBC) \= 3\.0 x 10^9/L
- •\- Serum bilirubin \= 2\.5 x Normal range
Exclusion Criteria
- •1\) Patients who are not histologically or cytologically small cell lung cancer
- •2\) Patients observed progression of disease after 2 cycles of first\-line chemoimmunotherapy (ACE regimen)
- •3\) Patients who have not completed primary ACE regimen up to 4 cycles
- •4\) Untreated active brain or central nervous system metastasis
- •5\) Uncontrolled cardiovascular disease (e.g., myocardial infarction and unstable angina within 3 months)
- •6\) an uncontrolled, active infectious disease
- •7\) a patient with autoimmune disease
- •8\) Pregnant women, lactating women, or pregnant women who do not use proper contraception.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer.Cisplatin-resistant urothelial cancerJPRN-UMIN000010957agasaki University Hospital15
Active, not recruiting
Phase 1
Selinexor in the treatment of patients with Refractory and/or Relapsed Richter's TransformatioEUCTR2014-001240-38-GBKaryopharm Therapeutics Inc.50
Active, not recruiting
Phase 1
Richters TransformatioInitial and Refractory/Relapsed Richters Transformation (RT)MedDRA version: 18.0Level: PTClassification code 10058728Term: Richter's syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-001240-38-DEKaryopharm Therapeutics, Inc.50
Active, not recruiting
Phase 1
Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor CancerAdvanced Colorectal cancer (CRC), pancreatic cancer or non-small cell lung cancer (NSCLC), and other indications dependent on emerging dataMedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10033605 Term: Pancreatic cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10033604Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001080-36-DEAmgen Incorporated197
Active, not recruiting
Phase 1
Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor CancerAdvanced Colorectal cancer (CRC), pancreatic cancer or non-small cell lung cancer (NSCLC), and other indications dependent on emerging dataMedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10033605 Term: Pancreatic cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10033604Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001080-36-BEAmgen Incorporated197